DUO XU: Open Payments
NPI 1508645771 · WOODBRIDGE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,240 in 50 payments from 15 companies in 2025. Trend: 2023 $71 · 2024 $2,130 · 2025 $1,240
Food & beverage: $1,156Education: $84
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 7 | $183 |
| Janssen Biotech, Inc. | 4 | $163 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $134 |
| Ipsen Biopharmaceuticals, Inc | 5 | $116 |
| ABBVIE INC. | 5 | $112 |
| Ardelyx, Inc. | 4 | $99 |
| Gilead Sciences, Inc. | 3 | $81 |
| PFIZER INC. | 3 | $80 |
| QOL Medical, LLC | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
Products named: REZDIFFRA, TREMFYA, XIFAXAN, IQIRVO, IBSRELA, Sucraid, DUPIXENT, RINVOQ.
Industry payments across VA — which companies pay providers there.
